fidaxomicin
Commercial- Indications
- Clostridioides difficile infection (CDI)
Company intelligence / Profile preview
Optimer Pharmaceuticals, Inc.
Jersey City, New Jersey, United Statessynapse.patsnap.com ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Optimer Pharmaceuticals developed and commercialized DIFICID (fidaxomicin) tablets for the treatment of Clostridium difficile-associated diarrhea in adults in the United States and Canada. The company was acquired by Cubist Pharmaceuticals in 2013.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
Astellas Pharma Europe Ltd.Par Pharmaceuticals, Inc.Cempra, Inc.Optimer Biotechnology, Inc.Scripps Research Institute
Beyond the preview
Go deeper on Optimer Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Optimer Pharmaceuticals, Inc..